Sumitomo Pharma Announces Completion of Asian Business Spin-off and Share Transfer to Marubeni Global Pharma
Osaka, Japan – July 31, 2025 – Sumitomo Pharma Co., Ltd. (hereinafter referred to as “Sumitomo Pharma”) today announced the successful completion of its previously disclosed corporate reorganization, which involved the company’s Asian business segment. The significant transaction includes a simplified absorption-type company split of its Asian operations and the subsequent transfer of shares to Marubeni Global Pharma Co., Ltd.
This momentous step signifies a strategic realignment for Sumitomo Pharma, aimed at optimizing its business structure and further enhancing its operational efficiency and focus. The company has been diligently working towards this divestiture, which is expected to unlock new avenues for growth and strategic development for both entities involved.
The simplified absorption-type company split saw the Asian business operations of Sumitomo Pharma being effectively separated. Following this division, Sumitomo Pharma completed the transfer of its shares related to these Asian operations to Marubeni Global Pharma Co., Ltd. This partnership with Marubeni Global Pharma is anticipated to bring valuable synergies and a renewed strategic direction to the newly formed entity.
Sumitomo Pharma has expressed its commitment to a smooth transition for all stakeholders, including employees, business partners, and customers within the Asian region. The company believes that this strategic maneuver will empower its Asian business to pursue tailored growth strategies, leveraging the strengths and resources of Marubeni Global Pharma, while allowing Sumitomo Pharma to concentrate its efforts on its core therapeutic areas and global strategic priorities.
Details regarding the specific terms of the transaction and the future operational plans for the divested Asian business under Marubeni Global Pharma’s stewardship are expected to be communicated by the respective companies.
Sumitomo Pharma wishes to thank all parties involved for their cooperation and support throughout this complex process. The company remains dedicated to its mission of contributing to the health and well-being of people worldwide through the provision of innovative pharmaceutical products and services.
（開示事項の経過）アジア事業の会社分割（簡易吸収分割）ならびに丸紅グローバルファーマ株式会社との株式譲渡に関する手続きの完了のお知らせ
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
住友ファーマ published ‘（開示事項の経過）アジア事業の会社分割（簡易吸収分割）ならびに丸紅グローバルファーマ株式会社との株式譲渡に関する手続きの完了のお知らせ’ at 2025-07-31 06:30. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.